• STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs
  • STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models
  • Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro's platform for developing dual-payload ADCs